PT-141 (Bremelanotide) research peptide — wholesale

Regulatory positioning: Rx-only · Approved drug. PT-141 (Bremelanotide) is an approved drug in select jurisdictions (US FDA, marketed as Vyleesi for hypoactive sexual desire disorder). Supplied as research-grade API against valid prescription. Subject to buyer compliance with applicable Rx regulations.

Overview

PT-141, also referenced by its International Nonproprietary Name Bremelanotide, is a synthetic cyclic seven-amino-acid heptapeptide research compound developed as a melanocortin receptor agonist. The sequence is Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-OH, with an acetylated N-terminus and a cyclic structure formed by an amide bond between the Asp side chain and the Lys α-amino group. The compound is supplied as a research-grade lyophilized peptide, intended for in-vitro melanocortin-3 and melanocortin-4 receptor (MC3R / MC4R) research, receptor-binding studies, and analytical method development. SPK Pharma India supplies PT-141 as a documented, lot-traceable research compound for distributors, contract manufacturers, and academic laboratories. The compound is supplied for research and analytical applications only, and the disambiguation from consumer-facing PT-141 product lines is important for research buyers — the SPK supply is a research-grade bulk material, not a finished dosage form.

Specifications

Research context

PT-141 is studied in cell-based research on the melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors, both Class A G-protein-coupled receptors that signal through the Gs pathway, with downstream effects on intracellular cAMP accumulation. In-vitro receptor-binding assays, cAMP signalling studies in MC3R / MC4R-expressing cell lines, and receptor selectivity studies across the melanocortin receptor family (MC1R through MC5R) are the typical research applications.

The cyclic heptapeptide structure, with the D-Phe residue at position 3 and the cyclic constraint, confers selectivity for the MC3R / MC4R receptors over the MC1R receptor. The compound is also used in research contexts where the cyclic constraint is the variable of interest, in studies that investigate the contribution of peptide cyclisation to receptor-binding affinity and selectivity. SPK Pharma India does not make therapeutic, clinical, diagnostic, or dosing claims for this product. The compound is supplied strictly for in-vitro research, analytical method development, and reference-standard work.

For researchers new to the compound, the standard analytical reference points are CAS 189691-06-3, the seven-amino-acid cyclic sequence, the calculated molecular weight of 1,025.18 g/mol, the lyophilized powder form, and the documented purity threshold (≥99% HPLC).

Packaging and supply

• 10 mg research vial — for method development, receptor-binding assays, and reference-standard qualification. Standard MOQ: 5 vials.
• Bulk pack — on application, for annual supply contracts and recurring orders.

Distributor pricing is available on application. Annual supply contracts with scheduled recurring dispatch are available for repeat buyers. Lead time for in-stock SKUs is typically 5 business days from purchase order confirmation; lead time for scheduled production is typically 4 to 6 weeks.

Quality and documentation

Every lot of PT-141 ships with a lot-matched Certificate of Analysis documenting identity (mass spectrometry and amino acid analysis), purity (HPLC), appearance, lot number, and synthesis batch reference. A representative sample of every lot is independently verified by a third-party analytical laboratory before release. MSDS is supplied with every shipment. The COA template, the lot-traceability workflow, and the third-party verification scope are documented on the Quality page.

Storage and handling

• Store at -20°C in the original sealed container.
• Protect from light and moisture. The Trp residue is mildly light-sensitive.
• Allow the sealed container to reach room temperature before opening, to avoid condensation.
• Reconstitute in sterile, low-endotoxin research-grade water or in a mild buffer at the working concentration required by the assay.
• Do not refreeze once reconstituted; aliquot and store at working concentration.
• For cyclic peptides, the ring structure is stable; gentle mixing is sufficient.

Shipping

PT-141 is shipped lyophilized in sealed vials within temperature-validated packaging. International lanes are routed through dedicated life-science logistics partners with cold-chain handling. Standard dispatch is within 5 business days of purchase order confirmation. SPK Pharma India ships to the United States, the European Union, the United Kingdom, Canada, MENA, APAC, and LATAM. Full export documentation, including commercial invoice, packing list, certificate of origin, COA, and MSDS, is included with every shipment. Destination-specific documentation is supported on request.

Compliance

PT-141 (Bremelanotide) is an approved drug in select jurisdictions (US FDA, marketed as Vyleesi for hypoactive sexual desire disorder). Supplied as research-grade API against valid prescription. Subject to buyer compliance with applicable Rx regulations. SPK Pharma India does not make therapeutic, clinical, diagnostic, or dosing claims for this product. The buyer is responsible for end-use classification in the destination jurisdiction, for the appropriate Rx / licence / controlled-substance documentation, and for ensuring that downstream handling is consistent with the regulatory positioning stated above.

Lead form CTA

To request a wholesale quote for PT-141 (Bremelanotide), contact the trade desk with the subject line "PT-141 wholesale quote" and your company details, expected volume, and destination country. Distributor pricing is available on application. The desk responds within one business day.

Related compounds

• Kisspeptin-10 — 10-amino-acid KISS1R agonist research peptide
• Ipamorelin — selective GHS pentapeptide research peptide
• Selank — tuftsin analogue heptapeptide research peptide
• Semax — ACTH 4-10 analogue heptapeptide research peptide
• FOXO4-DRI — 46-amino-acid D-retro-inverso research peptide